MediWound Past Earnings Performance

Past criteria checks 0/6

MediWound's earnings have been declining at an average annual rate of -32.1%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 5.7% per year.

Key information

-32.1%

Earnings growth rate

-17.5%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-5.7%
Return on equity-82.0%
Net Margin-142.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Are Trimming Their Forecasts

Nov 29
Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Are Trimming Their Forecasts

MediWound Is A Healthy Investment

Oct 29

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

Jul 23
Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

Jun 01
Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

May 07
Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Feb 28
We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

Feb 01
Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

Dec 18
MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Sep 29
MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

MediWound's NexoBrid for thermal burns in children gets EMA review

Sep 20

Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

Aug 11
Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M

Aug 09

MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review

Aug 03

MediWound adds 13% after favorable data for ulcer candidate

Jul 07

MediWound taps Tzvi Palash as COO

Jun 30

Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?

Jun 24
Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching MediWound's (NASDAQ:MDWD) Cash Burn Situation

Dec 07
Here's Why We're Watching MediWound's (NASDAQ:MDWD) Cash Burn Situation

MediWound: Adjusting My Strategy After NexoBrid CRL

Jul 28

Revenue & Expenses Breakdown

How MediWound makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:MDWD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2420-28128
30 Jun 2420-20117
31 Mar 2420-13117
31 Dec 2319-7127
30 Sep 2325-12128
30 Jun 2326-141210
31 Mar 2326-201110
31 Dec 2226-201110
30 Sep 2220-161010
30 Jun 2221-151010
31 Mar 2222-141010
31 Dec 2124-141010
30 Sep 2125-11910
30 Jun 2125-1099
31 Mar 2123-1098
31 Dec 2022-998
30 Sep 2021-1197
30 Jun 2019-1297
31 Mar 2036495
31 Dec 1932295
30 Sep 192712103
30 Jun 19231293
31 Mar 193-584
31 Dec 183-684
30 Sep 183-1486
30 Jun 183-1495
31 Mar 182-1595
31 Dec 172-1595
30 Sep 172-14105
30 Jun 172-16107
31 Mar 172-19128
31 Dec 162-19127
30 Sep 161-25139
30 Jun 161-23137
31 Mar 161-19136
31 Dec 151-22136
30 Sep 150-21135
30 Jun 150-22135
31 Mar 150-24135
31 Dec 140-19145
30 Sep 140-12115
30 Jun 140-1095
31 Mar 140-764

Quality Earnings: MDWD is currently unprofitable.

Growing Profit Margin: MDWD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MDWD is unprofitable, and losses have increased over the past 5 years at a rate of 32.1% per year.

Accelerating Growth: Unable to compare MDWD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDWD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: MDWD has a negative Return on Equity (-81.96%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 22:00
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MediWound Ltd. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MarisBMO Capital Markets Equity Research
Jason WittesBrean Capital
Michael GormanBTIG